Literature DB >> 26793377

Combination of cetuximab with radio-chemotherapy in patients with esophageal cancer: less is more!

Ralf-Dieter Hofheinz1, Melanie Kripp1, Sylvie Lorenzen1.   

Abstract

Entities:  

Year:  2015        PMID： 26793377      PMCID： PMC4703643          DOI： 10.3978/j.issn.2072-1439.2015.12.31

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  19 in total

1.  Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).

Authors:  Thomas Ruhstaller; Miklos Pless; Daniel Dietrich; Helmut Kranzbuehler; Roger von Moos; Peter Moosmann; Michael Montemurro; Paul M Schneider; Daniel Rauch; Oliver Gautschi; Walter Mingrone; Lucas Widmer; Roman Inauen; Peter Brauchli; Viviane Hess
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

2.  Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.

Authors:  Feng Wen; Ruilei Tang; Yaxiong Sang; Meng Li; Qiancheng Hu; Zedong Du; Yi Zhou; Pengfei Zhang; Xiaofeng He; Qiu Li
Journal:  Cancer Sci       Date:  2013-07-30       Impact factor: 6.716

3.  Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.

Authors:  Ricard Mesía; Michael Henke; Andre Fortin; Heikki Minn; Alejandro Cesar Yunes Ancona; Anthony Cmelak; Avi B Markowitz; Sebastien J Hotte; Simron Singh; Anthony T C Chan; Marco C Merlano; Krzysztof Skladowski; Alicia Zhang; Kelly S Oliner; Ari VanderWalde; Jordi Giralt
Journal:  Lancet Oncol       Date:  2015-01-15       Impact factor: 41.316

4.  In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.

Authors:  L Milas; K Mason; N Hunter; S Petersen; M Yamakawa; K Ang; J Mendelsohn; Z Fan
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

5.  Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.

Authors:  Geoffrey Y Ku; Benjamin A Haaland; Gilberto de Lima Lopes
Journal:  Cancer Chemother Pharmacol       Date:  2012-06-15       Impact factor: 3.333

6.  Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma.

Authors:  Yongshun Chen; Xiaoyuan Wu; Shanshan Bu; Chunyu He; Wen Wang; Jinsong Liu; Wei Guo; Bo Tan; Yanxia Wang; Jianhua Wang
Journal:  Cancer Sci       Date:  2012-09-14       Impact factor: 6.716

7.  Resistance to cetuximab in EGFR-overexpressing esophageal squamous cell carcinoma xenografts due to FGFR2 amplification and overexpression.

Authors:  Yi Zhang; Tiecheng Pan; Xiaoxuan Zhong; Cai Cheng
Journal:  J Pharmacol Sci       Date:  2014       Impact factor: 3.337

8.  Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Authors:  Timothy S Maughan; Richard A Adams; Christopher G Smith; Angela M Meade; Matthew T Seymour; Richard H Wilson; Shelley Idziaszczyk; Rebecca Harris; David Fisher; Sarah L Kenny; Edward Kay; Jenna K Mitchell; Ayman Madi; Bharat Jasani; Michelle D James; John Bridgewater; M John Kennedy; Bart Claes; Diether Lambrechts; Richard Kaplan; Jeremy P Cheadle
Journal:  Lancet       Date:  2011-06-05       Impact factor: 79.321

9.  Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.

Authors:  Thomas Crosby; Christopher N Hurt; Stephen Falk; Simon Gollins; Somnath Mukherjee; John Staffurth; Ruby Ray; Nadim Bashir; John A Bridgewater; J Ian Geh; David Cunningham; Jane Blazeby; Rajarshi Roy; Tim Maughan; Gareth Griffiths
Journal:  Lancet Oncol       Date:  2013-04-25       Impact factor: 41.316

10.  Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.

Authors:  Tom Waddell; Ian Chau; David Cunningham; David Gonzalez; Alicia Frances Clare Okines; Alicia Frances; Clare Okines; Andrew Wotherspoon; Claire Saffery; Gary Middleton; Jonathan Wadsley; David Ferry; Wasat Mansoor; Tom Crosby; Fareeda Coxon; David Smith; Justin Waters; Timothy Iveson; Stephen Falk; Sarah Slater; Clare Peckitt; Yolanda Barbachano
Journal:  Lancet Oncol       Date:  2013-04-15       Impact factor: 41.316
View more
  1 in total

1.  Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification.

Authors:  Yongxin Ren; Jianming Zheng; Shiming Fan; Linfang Wang; Min Cheng; Dongxia Shi; Wei Zhang; Renxiang Tang; Ying Yu; Longxian Jiao; Jun Ni; Haibin Yang; Huaqing Cai; Fang Yin; Yunxin Chen; Feng Zhou; Weihan Zhang; Weiguo Qing; Weiguo Su
Journal:  Oncotarget       Date:  2017-04-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.